What's in Tae Won Kim's pipeline?

Tae Won Kim has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Tae Won Kim's portfolio?

Top competitors by shared drug class: IRCCS Azienda Ospedaliero-Universitaria di Bologna.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tae-won-kim.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Tae Won Kim — Portfolio Competitive Intelligence Brief

Tae Won Kim pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tae Won Kim:

Cite this brief

Drug Landscape (2026). Tae Won Kim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tae-won-kim. Accessed 2026-05-14.